Monitoring of ALK Fusions and Mutations in Advanced ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients

被引：0
|
作者：
Mezquita, L. [1 ]
Remon, J. [1 ]
Nicotra, C. [2 ]
Noerholm, M. [3 ]
Brinkmann, K. [3 ]
Planchard, D. [4 ]
Jovelet, C. [5 ]
Auclin, E. [6 ]
Flinspach, C. [3 ]
Hurley, J. [3 ]
Skog, J. [7 ]
Gazzah, A. [2 ]
Caramella, C. [8 ]
Adam, J. [9 ]
Lacroix, L. [5 ]
Auger, N. [9 ]
Friboulet, L. [10 ]
Soria, J. [11 ,12 ]
Besse, B. [1 ]
机构：
[1] Gustave Roussy, Dept Med Oncol, Villejuif, France
[2] Gustave Roussy, Drug Dev Dept, Villejuif, France
[3] Exosome Diagnost GmbH, Martinsried, Germany
[4] Gustave Roussy, Med Oncol, Villejuif, France
[5] Gustave Roussy, Translat Res Lab, Villejuif, France
[6] Hop Georges Pompidou, Paris, France
[7] Exosome Diagnost Inc, Waltham, MA USA
[8] Gustave Roussy, Radiol Dept, Villejuif, France
[9] Gustave Roussy Canc Campus, Dept Med Biol & Pathol, Villejuif, France
[10] Gustave Roussy, Inserm U981 Lab, Villejuif, France
[11] Gustave Roussy Canc Campus, Drug Dev Dept, Paris, France
[12] Gustave Roussy Canc Campus, Inserm U981 Lab, Paris, France
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.03-013
引用
收藏
页码：S1954 / S1955
页数：2
相关论文
共 50 条
  • [21] An amplicon-based liquid biopsy for detecting ALK and ROS1 fusions and resistance mutations in advanced non-small cell lung cancer (NSCLC) patients.
    Mezquita, Laura
    Jovelet, Cecile
    Lacroix, Ludovic
    Planchard, David
    Recondo, Gonzalo
    Pailler, Emma
    Auclin, Edouard
    Plagnol, Vincent
    Howarth, Karen
    Morris, Clive D.
    Green, Emma
    Rouleau, Etienne
    Nicotra, Claudio
    Caramella, Caroline
    Adam, Julien
    Auger, Nathalie
    Farace, Francoise
    Friboulet, Luc
    Besse, Benjamin
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [22] Treating ALK-positive non-small cell lung cancer
    Ziogas, Dimitrios C.
    Tsiara, Anna
    Tsironis, Georgios
    Lykka, Maria
    Liontos, Michalis
    Bamias, Aristotelis
    Dimopoulos, Meletios-Athanasios
    ANNALS OF TRANSLATIONAL MEDICINE, 2018, 6 (08)
  • [23] ALK inhibitors and advanced non-small cell lung cancer (Review)
    Rossi, Antonio
    Maione, Paolo
    Sacco, Paola Claudia
    Sgambato, Assunta
    Casaluce, Francesca
    Ferrara, Marianna Luciana
    Palazzolo, Giovanni
    Ciardiello, Fortunato
    Gridelli, Cesare
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2014, 45 (02) : 499 - 508
  • [24] Number of untimely deaths prevented with ALK-inhibitors in Brazilian patients with advanced non-small cell lung cancer with ALK driver mutations
    Pellegrini, R. A.
    Lenz, G.
    Cruz, B. D.
    Lago, L. S.
    Azevedo, P. S.
    Torres, L. L.
    Lopes, G.
    Teodoro, J. A.
    ANNALS OF ONCOLOGY, 2020, 31 : S967 - S967
  • [25] The efficacy of ceritinib in patients with ALK-positive non-small cell lung cancer
    Kaczmar, John
    Mehra, Ranee
    THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, 2015, 9 (05) : 236 - 241
  • [26] Comparative analyses of overall survival of anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) patients who did not receive ALK inhibitors
    Kim, D.
    Lee, J. K.
    Park, H. S.
    Kulig, K.
    Kim, T. M.
    Lee, S.
    Jeon, Y.
    Chung, D. H.
    Heo, D. S.
    Kim, W. H.
    Bang, Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [27] Crizotinib: A targeted therapy in advanced ALK-positive non-small cell lung cancer
    Toffart, A. -C.
    Sakhri, L.
    Moro-Sibilot, D.
    REVUE DE PNEUMOLOGIE CLINIQUE, 2013, 69 (02) : 111 - 116
  • [28] Retrospective analysis of clinical outcomes of early stage ALK-positive (ALK plus ) non-small cell lung cancer (NSCLC).
    Dagogo-Jack, Ibiayi
    Santini, Fernando
    Eng, Juliana
    Yeap, Beow Y.
    Izar, Benjamin
    Chin, Emily
    Litvak, Anya
    Jones, David Randolph
    Kris, Mark G.
    Shaw, Alice Tsang
    Gainor, Justin F.
    Chaft, Jamie E.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [29] Clinical benefit from pemetrexed before and after crizotinib exposure in patients with ALK positive non-small cell lung cancer (ALK plus NSCLC).
    Berge, Eamon
    Delee, Maxon
    Lu, Xian
    Baron, Anna E.
    Solomon, Benjamin J.
    Doebele, Robert Charles
    Camidge, D. Ross
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [30] Long-term clinical outcomes of ALK inhibitors in patients with ALK-positive advanced non-small cell lung cancer.
    Murakami, Haruyasu
    Ono, Akira
    Nakashima, Kazuhisa
    Omori, Shota
    Wakuda, Kazushige
    Kenmotsu, Hirotsugu
    Naito, Tateaki
    Takahashi, Toshiaki
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
12345